GeneReach Biotechnology Corp. (TPEX:4171)

Market Cap	1.02B -9.7%
Revenue (ttm)	232.55M +9.2%
Net Income	-105.32M
EPS	-1.83
Shares Out	57.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	249,170
Open	17.80
Previous Close	17.80
Day's Range	17.75 - 18.45
52-Week Range	16.95 - 27.95
Beta	0.48
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About GeneReach Biotechnology

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assays, iiPCR Specific Reagents, research reagents and consumables, as well as taco Nucleic Acid Extraction Reagents, IQ REAL Quantitative System, and IQ20...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4171

Financial Performance

In 2025, GeneReach Biotechnology's revenue was 232.74 million, an increase of 12.71% compared to the previous year's 206.49 million. Losses were -110.28 million, -7.12% less than in 2024.